United States Drugs for Malaria Market Report 2022
Summary Malaria remains one of the most devastating infectious diseases with approximately 212 million infections and 429,000 deaths each year. In 2016, the revenue is 33.8 M USD.
This report studies sales (consumption) of drugs for malaria in USA market, focuses on top players, with revenue, gross margin and market share for each player, covering Cipla Guilin Pharmaceutical IPCA Laboratories GlaxoSmithKline Mylan Labs Roche Novartis Sanofi Aventis Ajanta Pharma
Split by product types, with revenue, market share and growth rate of each type, can be divided into Aryl Aminoalcohol Compounds Antifolate Compounds Artemisinin Compounds
Split by applications, this report focuses on revenue, market share and growth rate of
drugs for malaria in each application, can be divided into Prevention Treatment Other
Table of Contents 1 Drugs for Malaria Overview 1.1 Product Overview and Scope of Drugs for Malaria 1.2 Classification of Drugs for Malaria 1.2.1 Aryl Aminoalcohol Compounds 1.2.2 Antifolate Compounds 1.2.3 Artemisinin Compounds 1.3 Applications of Drugs for Malaria 1.3.1 Prevention 1.3.2 Treatment 1.4 Overview of Malaria 1.4.1 Overview Achievements from 2000 to 2015 of Malaria 1.4.2 Outlook for Progress from 2016 to 2030 of Malaria 1.5 United States Market Revenue of Drugs for Malaria (2011-2022)
2 United States Drugs for Malaria Competition by Manufacturers 2.1 United States Drugs for Malaria Revenue and Share by Manufacturers (2015 and 2016)
2.2 Drugs for Malaria Market Competitive Situation and Trends 2.2.1 Drugs for Malaria Market Concentration Rate 2.2.2 Drugs for Malaria Market Share of Top 3 and Top 5 Manufacturers 2.2.3 Mergers & Acquisitions, Expansion
3 United States Drugs for Malaria Revenue (Value) by Types (2011-2016) 3.1 United States Drugs for Malaria Revenue and Market Share by Types (2011-2016) 3.2 United States Drugs for Malaria Revenue Growth Rate by Types (2012-2016)
4 United States Drugs for Malaria Revenue (Value) by Applications (2011-2016) 4.1 United States Drugs for Malaria Revenue and Market Share by Applications (2011-2016) 4.2 United States Drugs for Malaria Revenue Growth Rate by Applications (2012-2016) 4.3 Market Drivers and Opportunities
5 United States Drugs for Malaria Manufacturers Profiles/Analysis 5.1 Cipla 5.1.1 Company Basic Information 5.1.2 Drugs for Malaria Product Information 5.1.3 Cipla Drugs for Malaria Revenue, Cost, Gross and Gross Margin (2015-2016) 5.1.4 Main Business/Business Overview 5.2 Guilin Pharmaceutical 5.2.1 Company Basic Information 5.2.2 Drugs for Malaria Product Information 5.2.3 Guilin Pharmaceutical Drugs for Malaria Revenue, Cost, Gross and Gross Margin (2015-2016) 5.2.4 Main Business/Business Overview 5.3 IPCA Laboratories 5.3.1 Company Basic Information 5.3.2 Drugs for Malaria Product Information 5.3.3 IPCA Laboratories Drugs for Malaria Revenue, Cost, Gross and Gross Margin
(2015-2016) 5.3.4 Main Business/Business Overview 5.4 GlaxoSmithKline 5.4.1 Company Basic Information 5.4.2 Drugs for Malaria Product Information 5.4.3 GlaxoSmithKline Drugs for Malaria Revenue, Cost, Gross and Gross Margin (2015-2016) 5.4.4 Main Business/Business Overview 5.5 Mylan Labs 5.5.1 Company Basic Information 5.5.2 Drugs for Malaria Product Information 5.5.3 Mylan Labs Drugs for Malaria Revenue, Cost, Gross and Gross Margin (2015-2016) 5.5.4 Main Business/Business Overview 5.6 Roche 5.6.1 Company Basic Information 5.6.2 Drugs for Malaria Product Information 5.6.3 Roche Drugs for Malaria Revenue, Cost, Gross and Gross Margin (2015-2016) 5.6.4 Main Business/Business Overview 5.7 Novartis 5.7.1 Company Basic Information 5.7.2 Drugs for Malaria Product Information 5.7.3 Novartis Drugs for Malaria Revenue, Cost, Gross and Gross Margin (2015-2016) 5.7.4 Main Business/Business Overview 5.8 Sanofi Aventis 5.8.1 Company Basic Information 5.8.2 Drugs for Malaria Product Information 5.8.3 Sanofi Aventis Drugs for Malaria Revenue, Cost, Gross and Gross Margin (2015-2016)
5.8.4 Main Business/Business Overview 5.9 Ajanta Pharma 5.9.1 Company Basic Information 5.9.2 Drugs for Malaria Product Information 5.9.3 Ajanta Pharma Drugs for Malaria Revenue, Price and Gross Margin (2012-2017) 5.9.4 Main Business/Business Overview
6 Drugs for Malaria Manufacturing Cost Analysis 6.1 Drugs for Malaria Key Raw Materials Analysis 6.1.1 Key Raw Materials 6.1.2 Price Trend of Key Raw Materials 6.1.3 Key Suppliers of Raw Materials 6.1.4 Market Concentration Rate of Raw Materials 6.2 Proportion of Manufacturing Cost Structure 6.2.1 Raw Materials 6.2.2 Labor Cost 6.2.3 Manufacturing Expenses 6.3 Manufacturing Process Analysis of Drugs for Malaria
7 Industrial Chain, Sourcing Strategy and Downstream Buyers 7.1 Drugs for Malaria Industrial Chain Analysis 7.2 Upstream Raw Materials Sourcing 7.3 Raw Materials Sources of Drugs for Malaria Major Manufacturers in 2016 7.4 Downstream Buyers
8 Marketing Strategy Analysis, Distributors/Traders 8.1 Marketing Channel 8.1.1 Direct Marketing 8.1.2 Indirect Marketing
8.1.3 Marketing Channel Development Trend 8.2 Market Positioning 8.2.1 Pricing Strategy 8.2.2 Brand Strategy 8.2.3 Target Client 8.3 Distributors/Traders List
9 Market Effect Factors Analysis 9.1 Technology Progress/Risk 9.1.1 Substitutes Threat 9.1.2 Technology Progress in Related Industry 9.2 Consumer Needs/Customer Preference Change 9.3 Economic/Political Environmental Change
10 United States Drugs for Malaria Market Forecast (2017-2022) 10.1 United States Drugs for Malaria Revenue Forecast (2017-2022) 10.2 United States Drugs for Malaria Revenue Forecast by Types (2017-2022) 10.3 United States Drugs for Malaria Revenue Forecast by Application (2017-2022)
11 Research Findings and Conclusion 12 Appendix Author List Key Source of the Report Disclosure Section Research Methodology Data Source Disclaimer